Bristol-Myers Squibb Co. (BMY)

54.68
0.46 0.83
NYSE : Health Technology
Prev Close 55.14
Open 55.00
Day Low/High 54.98 / 55.33
52 Wk Low/High 49.96 / 70.05
Volume 663.98K
Avg Volume 8.71M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 88.17B
EPS 0.60
P/E Ratio 93.00
Div & Yield 1.60 (2.91%)
Bristol-Myers Squibb Bulls Take a Short Break

Bristol-Myers Squibb Bulls Take a Short Break

There is strong support just below the market for drug giant.

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

It depends on which aisle of the stock market you're on.

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) For Treatment Of Patients With Resected High-Risk Advanced Melanoma

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) For Treatment Of Patients With Resected High-Risk Advanced Melanoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) to...

Where Have All the Buyers Gone?; Safety Dance -- Jim Cramer's Top Thoughts

Where Have All the Buyers Gone?; Safety Dance -- Jim Cramer's Top Thoughts

Cramer reflects on where all the buyers have gotten to and also discusses the stock market's safety dance.

Big Opportunities to Buy Stocks Have Secretly Emerged

Big Opportunities to Buy Stocks Have Secretly Emerged

The stock market has had a wild week. Some interesting opportunities may have finally emerged.

Rethinking Risk and Reward: Cramer's 'Mad Money' Recap (Thursday 10/26/17)

Rethinking Risk and Reward: Cramer's 'Mad Money' Recap (Thursday 10/26/17)

Jim Cramer says that in this market, what we thought were safe stocks are now risky, and the dangerous ones have become the safer bets.

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Alexion Pharmaceuticals, Bristol-Myers Squibb and Celgene were among the healthcare firms that unveiled quarterly numbers on Oct. 26.

Cramer: Stock Market's 'Safety Dance' Has Reversed

Cramer: Stock Market's 'Safety Dance' Has Reversed

What was dangerous is now safe, what was safe is now risky.

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Shares of Celgene are down more than 30% so far this month and almost 20% Thursday as the company cuts full-year and 2020 guidance.

Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2017, which were highlighted by strong sales for key products Opdivo and Eliquis and multiple regulatory approvals for...

Tuesday Was Blacker Than Monday; Tax Reform's Role -- Jim Cramer's Top Thoughts

Tuesday Was Blacker Than Monday; Tax Reform's Role -- Jim Cramer's Top Thoughts

Cramer reflects on how the day after Black Monday was worse and also discusses the current role of tax reform.

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

A decision should be made 'in the coming days.'

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

A string of severe hurricanes that swept across the south and southeastern portions of the U.S. and Puerto Rico toward the end of the third quarter could put a big dent in economic growth.

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Jim Cramer's game plan is jam-packed for next week; this is the heart of earnings season.

Bristol-Myers Squibb To Present New Data Advancing Research Across Serious Liver Diseases At The Liver Meeting® 2017

Bristol-Myers Squibb To Present New Data Advancing Research Across Serious Liver Diseases At The Liver Meeting® 2017

Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), will be presented at The Liver...

Cramer: What's Tax Reform Got to Do With It?

Cramer: What's Tax Reform Got to Do With It?

Treasury secretary says it's baked into the market, but is anyone really counting on it?

Allergan Isn't Feeling Any Better

Restasis ruling still weighs on stock, which is too cheap to sell now.

Merck Stock Edges Higher as Citi Forecasts Strong Sales

Merck Stock Edges Higher as Citi Forecasts Strong Sales

Citi analysts say Merck's Keytruda immunotherapy cancer drug will carry the company.

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

Healthcare Drives Small Gains for Dow While Rest of Market Slips

Healthcare Drives Small Gains for Dow While Rest of Market Slips

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

Earnings beats from UnitedHealth Group Inc. and Johnson & Johnson led the healthcare sector to recover from a days-long presidential beating.

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

Apple gains offset weakness in the healthcare sector. Small increases for benchmark indexes were enough to lead them to new closing records.

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Stocks are higher but retreat from intraday records on Monday.

Opdivo Alone Or Combined With Yervoy Shows Encouraging Response And Survival Rates In Recurrent Small Cell Lung Cancer Patients With High Tumor Mutation Burden, In Exploratory Analysis From Phase 1/2 Study CheckMate -032

Opdivo Alone Or Combined With Yervoy Shows Encouraging Response And Survival Rates In Recurrent Small Cell Lung Cancer Patients With High Tumor Mutation Burden, In Exploratory Analysis From Phase 1/2 Study CheckMate -032

Bristol-Myers Squibb Company (NYSE:BMY) today announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in previously treated small cell lung cancer (SCLC) patients whose tumors were evaluable for...

Why Some Think It's 'Prime Time' for Amazon to Enter the Pharmacy Market

Why Some Think It's 'Prime Time' for Amazon to Enter the Pharmacy Market

The move is a natural for the e-commerce giant, and could wind up dramatically reducing the price of prescription drugs, according to Morgan Stanley.

Mazor Robotics, Iridium, ZAGG: 'Mad Money' Lightning Round

Mazor Robotics, Iridium, ZAGG: 'Mad Money' Lightning Round

A roundup of companies callers asked Jim Cramer about on Mad Money.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Investors Are Scooping Up Shares of Apple, Ditching Bristol Myers and Pfizer

Investors Are Scooping Up Shares of Apple, Ditching Bristol Myers and Pfizer

Investors rolled into shares of Apple in September, according to TD Ameritrade, but took profits on shares of Bristol-Myers and Pfizer shares.

TheStreet Quant Rating: C (Hold)